Physician profile
Melissa Edwards
NPI 1598252173
$2,918.23
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,461 · 2022: $1,117 · 2023: $222 · 2024: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.81 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $305.28 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $282.13 | 2021-2022 | |
| Alkermes, INC. | $251.15 | 2021-2023 | Aristada, Lybalvi |
| Acadia Pharmaceuticals INC | $241.66 | 2021-2024 | Nuplazid |
| Vanda Pharmaceuticals INC. | $228.79 | 2021-2023 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.74 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $174.21 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $113.68 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $81.05 | 2021-2022 | |
| Adlon Therapeutics L.P. | $70.46 | 2021 | |
| Ironshore Pharmaceuticals INC. | $69.70 | 2022 | |
| Viiv Healthcare Company | $68.36 | 2021 | |
| Eisai INC. | $60.99 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $51.92 | 2021-2023 | Austedo Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $45.35 | 2021 | |
| Bausch Health US, LLC | $33.60 | 2021 | |
| Lundbeck LLC | $28.35 | 2022 | |
| Corium, LLC | $24.52 | 2021 | |
| Janssen Scientific Affairs, LLC | $24.21 | 2022 | |
| Indivior INC. | $23.87 | 2022 | |
| Biogen, INC. | $18.68 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.72 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.